# Feature Synergy Map

**Version:** 1.0.0
**Created:** December 29, 2025
**Status:** Planning Phase

---

## Overview

This document maps the interdependencies and synergies between the 100 features. Understanding these relationships is crucial for optimal implementation ordering and maximizing the value of each feature.

---

## Synergy Categories

### 1. Hard Dependencies
Feature B **requires** Feature A to be implemented first.
```
A ──────► B
```

### 2. Soft Dependencies
Feature B **benefits from** Feature A but can work independently.
```
A - - - -► B
```

### 3. Mutual Enhancement
Features A and B **enhance each other** when both implemented.
```
A ◄─────► B
```

### 4. Enabler
Feature A **enables/unlocks** multiple downstream features.
```
A ──────► B, C, D
```

---

## Master Dependency Graph

```
                                    FOUNDATION
                                        │
            ┌───────────────────────────┼───────────────────────────┐
            │                           │                           │
            ▼                           ▼                           ▼
    ┌───────────────┐           ┌───────────────┐           ┌───────────────┐
    │ #51 Self-Sup  │           │ #36 Conformal │           │ #16 5-adic    │
    │ Pre-training  │           │  Prediction   │           │   Encoder     │
    └───────┬───────┘           └───────┬───────┘           └───────┬───────┘
            │                           │                           │
    ┌───────┴───────────┐       ┌───────┴───────┐           ┌───────┴───────┐
    │                   │       │               │           │               │
    ▼                   ▼       ▼               ▼           ▼               ▼
┌───────┐         ┌───────┐ ┌───────┐     ┌───────┐   ┌───────┐       ┌───────┐
│#1-15  │         │ #56   │ │ #37   │     │ #38   │   │ #17   │       │ #57   │
│Disease│         │Hier.  │ │Temp   │     │Bayes  │   │7-adic │       │VQ-VAE │
│Analyz.│         │VAE    │ │Scale  │     │NN     │   │Struct │       │Codons │
└───┬───┘         └───┬───┘ └───┬───┘     └───┬───┘   └───┬───┘       └───┬───┘
    │                 │         │             │           │               │
    │                 ▼         │             │           │               │
    │           ┌───────────────┴─────────────┴───┐       │               │
    │           │                                 │       │               │
    │           ▼                                 ▼       ▼               ▼
    │     ┌───────────┐                     ┌───────────────────────────────┐
    │     │ #82 Clin. │                     │   #18-25 Advanced Encoding    │
    │     │ API       │                     │   Multi-prime, Wavelets, etc. │
    │     └─────┬─────┘                     └───────────────────────────────┘
    │           │
    │     ┌─────┴─────────────────────┐
    │     │                           │
    │     ▼                           ▼
    │ ┌───────┐                   ┌───────┐
    │ │ #81   │                   │ #88   │
    │ │FHIR   │                   │Surveil│
    │ │Integ. │                   │Dashbd │
    │ └───────┘                   └───────┘
    │
    └──────────────────────► FULL PLATFORM
```

---

## Detailed Dependency Chains

### Chain 1: Clinical Pipeline
**Theme:** From uncertainty to clinical deployment

```
#36 Conformal Prediction
 │
 ├──► #37 Temperature Scaling
 │     │
 │     └──► #82 Clinical Decision API
 │           │
 │           ├──► #81 FHIR R4 Integration
 │           │
 │           ├──► #83 Automated Reports
 │           │
 │           ├──► #84 Clinical Alerts
 │           │     │
 │           │     └──► #85 Drug Interaction (+ #71 Epistasis)
 │           │
 │           └──► #88 Surveillance Dashboard
 │
 ├──► #38 Bayesian Neural Networks
 │     │
 │     └──► #39 Ensemble Uncertainty
 │           │
 │           └──► #40 Epistemic vs Aleatoric
 │
 ├──► #41 OOD Detection
 │
 ├──► #42 Selective Prediction
 │
 └──► #44 Calibration Under Shift
```

**Synergies:**
- #36 + #37: Temperature scaling improves conformal efficiency
- #38 + #39: Ensembles can be Bayesian for dual uncertainty
- #82 + #81: API provides data for FHIR transformation
- #84 + #85: Drug interactions inform alert severity

---

### Chain 2: Transfer Learning Pipeline
**Theme:** Knowledge transfer across diseases

```
#51 Self-Supervised Pre-training
 │
 ├──► #47 Cross-Disease Pre-training
 │
 ├──► #52 Task-Agnostic Representations
 │
 ├──► #100 Federated Learning
 │
 └──► #46 Domain Adversarial Transfer
       │
       ├──► #48 Meta-Learning Adaptation
       │
       ├──► #49 Progressive Transfer
       │
       ├──► #50 Contrastive Transfer
       │
       └──► #55 Continual Learning
             │
             └──► Multiple diseases without forgetting

#53 Adapter Modules ─────► #54 LoRA for VAE
     │
     └──► Parameter-efficient fine-tuning
```

**Synergies:**
- #51 + #46: Pre-training provides features for adversarial alignment
- #48 + #53: Meta-learning can adapt adapters efficiently
- #100 + #51: Federated learning uses pre-trained initialization
- #53 + #54: Can combine adapters with LoRA for extreme efficiency

---

### Chain 3: Encoding Evolution
**Theme:** From basic to sophisticated sequence encoding

```
#16 5-adic Amino Acid Encoder
 │
 ├──► #17 7-adic Secondary Structure
 │     │
 │     └──► Structure-aware resistance prediction
 │
 ├──► #57 VQ-VAE for Codons
 │     │
 │     └──► Discrete latent space
 │
 └──► #18 Multi-Prime Fusion
       │
       ├──► #19 Adaptive Prime Selection
       │     │
       │     └──► Automatic best prime per position
       │
       ├──► #20 P-adic Wavelet
       │
       ├──► #21 Codon Context Window
       │
       ├──► #22 Position-Aware P-adic
       │
       ├──► #23 Mutation-Type Embedding
       │
       ├──► #24 Reading Frame Encoding
       │
       └──► #25 Synonymous Codon Encoding
```

**Synergies:**
- #16 + #17: Amino acid + structure = comprehensive protein view
- #18 + #19: Fusion benefits from adaptive selection
- #20 + #22: Wavelets work well with position awareness
- #23 + #25: Mutation type + synonymous = full codon picture

---

### Chain 4: Hyperbolic Geometry Evolution
**Theme:** Advanced manifold representations

```
[Existing Poincaré Ball]
 │
 ├──► #26 Multi-Sheet Hyperbolic
 │     │
 │     └──► Disease taxonomy representation
 │
 ├──► #29 Adaptive Curvature
 │     │
 │     └──► Per-disease optimal curvature
 │
 ├──► #30 Hyperbolic Attention
 │     │
 │     └──► Hierarchical attention patterns
 │
 └──► #27 Hyperbolic Normalizing Flows
       │
       └──► #34 Hyperbolic Diffusion
             │
             └──► Generative modeling on manifold

#28 Product Manifold Spaces
 │
 └──► H^n x E^m for mixed data

#31 Geodesic Interpolation ──► #77 Evolutionary Trajectory

#32 Hyperbolic Clustering ──► #1-15 Disease Analyzers (taxonomy)

#33 Busemann Functions ──► Phylogenetic analysis

#35 Multi-Scale Hyperbolic ──► Coarse-to-fine predictions
```

**Synergies:**
- #26 + #29: Multi-sheet with adaptive curvature per sheet
- #27 + #34: Flows enable diffusion on manifold
- #30 + #58: Hyperbolic attention for attention-based VAE
- #31 + #77: Geodesics trace evolutionary paths
- #32 + #1-15: Clustering organizes disease variants

---

### Chain 5: Architecture Evolution
**Theme:** VAE architecture improvements

```
[Existing SimpleVAE]
 │
 ├──► #56 Hierarchical VAE
 │     │
 │     ├──► #64 Two-Stage VAE
 │     │
 │     └──► #71 Tensor Epistasis (multi-level interactions)
 │
 ├──► #58 Attention-Based VAE
 │     │
 │     └──► #30 Hyperbolic Attention
 │
 ├──► #59 Flow-Based Decoder
 │
 ├──► #60 Disentangled VAE
 │     │
 │     └──► #52 Task-Agnostic Representations
 │
 ├──► #61 Conditional VAE
 │     │
 │     └──► Drug/disease-specific generation
 │
 ├──► #62 Semi-Supervised VAE
 │
 ├──► #63 Info-VAE
 │
 ├──► #65 Sparse VAE
 │
 ├──► #66 Recurrent VAE
 │
 ├──► #67 Wasserstein VAE
 │
 ├──► #68 Multi-Modal VAE
 │     │
 │     └──► Sequence + Structure input
 │
 ├──► #69 Memory-Augmented VAE
 │
 └──► #70 Neural ODE VAE
```

**Synergies:**
- #56 + #60: Hierarchical disentanglement
- #58 + #66: Attention over recurrent states
- #61 + #68: Conditional on modality
- #63 + #67: Both avoid posterior collapse differently
- #69 + #55: Memory helps continual learning

---

### Chain 6: Epistasis Suite
**Theme:** Mutation interaction modeling

```
#71 Tensor Epistasis Network
 │
 ├──► #72 Sparse Epistasis
 │
 ├──► #73 Temporal Epistasis
 │     │
 │     └──► #77 Evolutionary Trajectory
 │
 ├──► #74 Cross-Gene Epistasis
 │
 ├──► #75 Compensatory Mutations
 │     │
 │     └──► #86 Treatment Recommendation
 │
 ├──► #76 Fitness Landscape
 │     │
 │     └──► #77 Evolutionary Trajectory
 │
 ├──► #78 Mutation Order Effects
 │
 ├──► #79 Codon-Level Epistasis
 │     │
 │     └──► #25 Synonymous Codon Encoding
 │
 └──► #80 Structural Epistasis
       │
       └──► #68 Multi-Modal VAE (structure input)
```

**Synergies:**
- #71 + #72: Tensor factorization for sparse interactions
- #73 + #77: Temporal dynamics reveal trajectories
- #75 + #78: Order effects explain compensation
- #76 + #77: Landscape enables trajectory prediction
- #79 + #25: Codon encoding captures codon-level effects
- #80 + #68: Structure input enables structural epistasis

---

### Chain 7: Disease Analyzer Network
**Theme:** Cross-disease knowledge sharing

```
                    [Existing 11 Analyzers]
                            │
            ┌───────────────┼───────────────┐
            │               │               │
            ▼               ▼               ▼
      ┌─────────┐     ┌─────────┐     ┌─────────┐
      │  Viral  │     │Bacterial│     │ Cancer  │
      └────┬────┘     └────┬────┘     └────┬────┘
           │               │               │
    ┌──────┴──────┐   ┌────┴────┐         │
    │             │   │         │         │
    ▼             ▼   ▼         ▼         ▼
┌───────┐    ┌───────┐ ┌───────┐ ┌───────┐
│Flaviv.│    │Resp.  │ │Entero-│ │Nosoco-│
│#1,2,5,6    │#3,4,10│ │bacter │ │mial   │
└───┬───┘    └───────┘ │#11-13 │ │#14,15 │
    │                  └───────┘ └───────┘
    │
    ▼
Cross-family transfer (#46)
```

**Disease Family Synergies:**

| Family | Members | Shared Features |
|--------|---------|-----------------|
| Flaviviruses | #1 Dengue, #2 Zika, #5 West Nile | NS3/NS5 targets, serotype handling |
| Respiratory | #3 Norovirus, #4 Entero, #10 Adeno | RdRp targets, outbreak tracking |
| Herpesviruses | #8 EBV, #9 CMV | Kinase inhibitor resistance |
| Enterobacteriaceae | #12 E. coli, #13 Klebsiella | ESBL/carbapenemase, mcr genes |
| Non-fermenters | #14 Acinetobacter, #15 Pseudomonas | Efflux, biofilm |

---

### Chain 8: Training Optimization
**Theme:** Efficient and scalable training

```
#91 Mixed Precision
 │
 ├──► #92 Gradient Checkpointing
 │     │
 │     └──► Enables larger models
 │
 ├──► #93 Distributed Training
 │     │
 │     └──► #100 Federated Learning
 │
 └──► #94 Dynamic Batching
       │
       └──► Better GPU utilization

#95 Curriculum Learning
 │
 └──► Faster convergence

#96 Label Smoothing ──► #36 Conformal (better calibration)

#97 SWA ──► #38 Bayesian (SWA-Gaussian)

#98 Knowledge Distillation
 │
 └──► Edge deployment

#99 Neural Architecture Search
 │
 └──► All architecture features (#56-70)
```

**Synergies:**
- #91 + #92 + #93: Combined enable very large models
- #95 + #51: Curriculum for pre-training
- #96 + #37: Both improve calibration
- #97 + #38: SWA-Gaussian for Bayesian uncertainty
- #98 + #99: Distill NAS-found architecture

---

## Cross-Category Synergy Matrix

| Category | Disease | Encoding | Hyperbolic | Uncertainty | Transfer | Architecture | Epistasis | Clinical | Training |
|----------|---------|----------|------------|-------------|----------|--------------|-----------|----------|----------|
| **Disease** | - | High | Medium | High | High | Medium | High | Critical | Medium |
| **Encoding** | High | - | Medium | Low | High | High | Medium | Low | Medium |
| **Hyperbolic** | Medium | Medium | - | Medium | High | High | High | Low | Low |
| **Uncertainty** | High | Low | Medium | - | Medium | Medium | Low | Critical | Medium |
| **Transfer** | High | High | High | Medium | - | High | Medium | Medium | High |
| **Architecture** | Medium | High | High | Medium | High | - | High | Medium | High |
| **Epistasis** | High | Medium | High | Low | Medium | High | - | High | Low |
| **Clinical** | Critical | Low | Low | Critical | Medium | Medium | High | - | Low |
| **Training** | Medium | Medium | Low | Medium | High | High | Low | Low | - |

**Legend:**
- **Critical:** Must have for the other category to function
- **High:** Strong synergy, significant improvement
- **Medium:** Moderate synergy, noticeable improvement
- **Low:** Minimal synergy, independent operation

---

## Top 10 Highest-Synergy Feature Pairs

| Rank | Feature A | Feature B | Synergy Score | Description |
|------|-----------|-----------|---------------|-------------|
| 1 | #51 Self-Sup | #46 Domain Adv | 10 | Pre-training + adversarial = best transfer |
| 2 | #36 Conformal | #82 Clinical API | 10 | Calibration required for clinical use |
| 3 | #71 Epistasis | #75 Compensatory | 9 | Tensor enables compensatory detection |
| 4 | #56 Hier VAE | #60 Disentangled | 9 | Hierarchical disentanglement |
| 5 | #16 5-adic | #18 Multi-Prime | 9 | Foundation for fusion |
| 6 | #26 Multi-Sheet | #32 Clustering | 8 | Sheets for taxonomy clustering |
| 7 | #38 Bayesian | #40 Epi/Aleatoric | 8 | BNN enables decomposition |
| 8 | #81 FHIR | #88 Dashboard | 8 | FHIR data feeds dashboard |
| 9 | #77 Trajectory | #76 Landscape | 8 | Landscape enables trajectory |
| 10 | #91 Mixed Prec | #93 Distributed | 8 | Combined scaling |

---

## Implementation Synergy Clusters

### Cluster A: Clinical Readiness
**Features:** #36, #37, #38, #39, #40, #41, #42, #82, #81, #83, #84, #88
**Rationale:** All needed for clinical deployment
**Implement Together:** Yes, Phase 1 + Phase 4

### Cluster B: Advanced Encoding
**Features:** #16, #17, #18, #19, #20, #21, #22, #23, #24, #25, #57
**Rationale:** Build on each other progressively
**Implement Together:** Sequential, Phases 1-6

### Cluster C: Transfer Learning Stack
**Features:** #46, #47, #48, #49, #50, #51, #52, #53, #54, #55, #100
**Rationale:** Pre-train → fine-tune pipeline
**Implement Together:** Yes, after #51

### Cluster D: Epistasis Suite
**Features:** #71, #72, #73, #74, #75, #76, #77, #78, #79, #80, #85
**Rationale:** All depend on tensor network
**Implement Together:** After #71

### Cluster E: Hyperbolic Innovation
**Features:** #26, #27, #28, #29, #30, #31, #32, #33, #34, #35
**Rationale:** Advanced manifold features
**Implement Together:** Research phase, flexible order

### Cluster F: Architecture Lab
**Features:** #56, #57, #58, #59, #60, #61, #62, #63, #64, #65, #66, #67, #68, #69, #70
**Rationale:** VAE variants to test
**Implement Together:** Can parallelize experiments

---

## Dependency Count Analysis

### Most Dependent Features (need many prerequisites)

| Feature | Dependencies | Critical Path |
|---------|--------------|---------------|
| #88 Surveillance Dashboard | 5 | #36 → #82 → #81 → #88 |
| #100 Federated Learning | 4 | #51 → #93 → #100 |
| #77 Evolutionary Trajectory | 4 | #71 → #76 → #77 |
| #85 Drug Interaction | 3 | #71 → #82 → #85 |
| #34 Hyperbolic Diffusion | 3 | #27 → #34 |

### Most Enabling Features (unlock many others)

| Feature | Unlocks | Impact |
|---------|---------|--------|
| #51 Self-Supervised | 15+ | Foundation for all transfer |
| #36 Conformal | 10+ | Foundation for clinical |
| #56 Hierarchical VAE | 8+ | Foundation for architecture |
| #71 Tensor Epistasis | 10 | Foundation for epistasis |
| #16 5-adic Encoder | 9 | Foundation for encoding |

---

## Anti-Patterns (Avoid These Orderings)

| Anti-Pattern | Why Bad | Correct Order |
|--------------|---------|---------------|
| #82 before #36 | API needs calibration | #36 → #82 |
| #81 before #82 | FHIR transforms API output | #82 → #81 |
| #77 before #76 | Trajectory needs landscape | #76 → #77 |
| #19 before #16 | Adaptive needs base encoder | #16 → #19 |
| #100 before #51 | Federated needs pre-training | #51 → #100 |
| #80 before #68 | Structural epistasis needs structure | #68 → #80 |

---

## Change Log

| Date | Version | Changes |
|------|---------|---------|
| 2025-12-29 | 1.0.0 | Initial synergy map |
